Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer

Part of paid clinical trials in Columbus, Ohio.

Sponsor
Ohio State University Comprehensive Cancer Center
Study ID
NCT03199651
Status
Recruiting
Apply to this trial

Conditions

  • Cigarette Smoker
  • Current Smoker
  • Lung Adenocarcinoma
  • Squamous Cell Lung Carcinoma
  • Stage IV Non-Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Best Practice — OTHER
    Receive usual care
  • Biospecimen Collection — PROCEDURE
    Undergo collection of tumor tissue and blood sample for repository
  • Biospecimen Collection — PROCEDURE
    Undergo tumor tissue and blood sample for AGIT/DS
  • Laboratory Biomarker Analysis — OTHER
    Correlative studies
  • Medical Chart Review — OTHER
    Undergo medical record abstraction
  • Quality-of-Life Assessment — OTHER
    Ancillary studies
  • Questionnaire Administration — OTHER
    Ancillary studies
  • Smoking Cessation Intervention — BEHAVIORAL
    Undergo usual care or NCCN-driven CTC/DS

Study Details

This randomized clinical trial studies the Beating Lung Cancer in Ohio protocol in improving survival in patients with stage IV non-small cell lung cancer. The Beating Lung Cancer in Ohio protocol may help in evaluating immunotherapies and targeted therapies that prolong survival, have more favorable toxicity profiles than conventional chemotherapy and impact quality of life.

Key Dates

Start date
Jul 17, 2017
Status verified
Feb 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2028

Study Design

Enrollment
3,584 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Active Comparator: Arm I (UC)
    Patients receive usual care and undergo collection of tumor tissue and blood sample for the repository. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
  • Experimental: Arm II (AGIT/DS)
    Patients undergo collection of tumor tissue for analysis using FoundationOne assay and blood sample for analysis using FoundationACT blood circulating tumor DNA assay. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.

Primary Outcome Measure

Cost-Effectiveness Analysis [ Time Frame: Up to 24 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Ohio State University Comprehensive Cancer CenterColumbusOhio43210
Peter G. Shields, MD
[email protected]
614-688-6563
Peter G. Shields, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Columbus, OH

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Ohio State University Comprehensive Cancer Center· Columbus, OH

Related Studies